Atria Wealth Solutions, Inc. Neurocrine Biosciences Inc Transaction History

Atria Wealth Solutions, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Aug 22, 2023	BUY	$94.11 - $123.02 $342,654 - $447,915	3,641 New	3,641 $368,000
Q1 2023 Jun 14, 2023	BUY	$94.11 - $123.02 $1,129 - $1,476	12 Added 0.33%	3,653 $369,000
Q1 2023 May 10, 2023	SELL	$94.11 - $123.02 $1,129 - $1,476	-12 Reduced 0.33%	3,641 $368,000
Q4 2022 Aug 30, 2023	BUY	$106.72 - $127.06 $389,848 - $464,150	3,653 New	3,653 $436,000
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $5,976 - $7,115	56 Added 1.56%	3,653 $436,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $39,664 - $46,466	-431 Reduced 10.7%	3,597 $382,000
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $43,048 - $56,839	-568 Reduced 12.36%	4,028 $393,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $332,980 - $435,746	4,596 New	4,596 $431,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.